search
Back to results

Use of Varenicline for 4-weeks Prior to Quitting

Primary Purpose

Tobacco Dependence, Smoking Cessation

Status
Completed
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
Varenicline
Placebo
Sponsored by
Queen Mary University of London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Dependence focused on measuring Smoking cessation, Tobacco dependence, Varenicline, Preloading

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Smokers seeking treatment
  • Aged 18 and over
  • Consenting to take part in the trial

Exclusion Criteria:

  • Pregnant or breastfeeding
  • End-stage renal disease
  • Used varenicline in the past 6 months
  • Unable to fill in questionnaires in English
  • Current psychiatric illness
  • Current serious illness including uncontrolled hypertension and recent cardiac event
  • Sensitivity to varenicline currently enrolled in other research projects.

Sites / Locations

  • Tobacco Dependence Research and Treatment Unit

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Varenicline pre-treatmemt

Placebo

Arm Description

Participants will use varenicline (1mg BD) 4-weeks prior to quitting

Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting

Outcomes

Primary Outcome Measures

Rating of Urges to Smoke 24 Hours and One Week After the Target Quit Date Assessed by Mood and Physical Symptoms Scale
The scale measures tobacco withdrawal symptoms (depressed, irritable, restless, hungry, poor concentration, slept worse than usual) on 5-point scales from Not at all (rated as 1) to Extremely (rated as 5). It also asks 'How much of the time have you felt the urge to smoke in the last week? and 'How strong have these urges been?'; both rated on 6-point scales with higher numbers=higher craving.

Secondary Outcome Measures

Change in Pre-quit End-expired Carbon Monoxide Reading (CO)
Carbon monoxide concentration is measured in particles per million. It indicates smoke intake. CO was measured at each contact to monitor changes in smoke intake and differences between the study arms.
Change in Pre-quit Cotinine Levels
Differences in baseline cotinine levels were compared with cotinine levels measured 4 weeks after taking the first medication dose.
Change in Pre-quit Ratings of Cigarette Satisfaction
Satisfaction measured on a scale of 1-5; "Have you found your cigarettes more or less enjoyable than usual in the last week?" 1= much more and 5 = much less
Change in Pre-quit Cigarette Consumption
Participants reported average number of cigarettes smoked per day every week throughout the four week pre-quit period.
Change in MPSS Scores of Urges to Smoke and Cigarette Withdrawal Symptoms Throughout the First Four Weeks of Abstinence
Change in the Mood and Physical Symptoms Scale (MPSS)*, scores of urges to smoke and cigarette withdrawal symptoms throughout the first four weeks of abstinence (measured weekly from weeks 4-8). * The MPSS measures cigarette withdrawal symptoms. The scale is 1-5, 1 being not at all and 5 being extremely (depressed, irritable, restless, hungry, poor concentration, slept worse than usual).

Full Information

First Posted
November 7, 2008
Last Updated
November 18, 2013
Sponsor
Queen Mary University of London
search

1. Study Identification

Unique Protocol Identification Number
NCT00789074
Brief Title
Use of Varenicline for 4-weeks Prior to Quitting
Official Title
Effects of an Extended Period of Varenicline Use Prior to Quitting Smoking on Post-quitting Urges to Smoke
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
March 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Queen Mary University of London

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Varenicline (Champix) is a relatively new medicine that is effective in helping people to quit smoking. It is normally started 1-week before stopping smoking and used for up to 12-24 weeks. We are trying to find out if using varenicline for an extended time (4-weeks) before stopping smoking is better than the standard 1-week of use prior to stopping. The study will recruit 100 smokers who want to stop. They will be randomly allocated to receive varenicline(4-weeks) or placebo (3-weeks followed by 1-week of active treatment as indicated by standard prescribing practice), followed by a 12-week open label treatment period where all participants will receive varenicline.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Dependence, Smoking Cessation
Keywords
Smoking cessation, Tobacco dependence, Varenicline, Preloading

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
101 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Varenicline pre-treatmemt
Arm Type
Experimental
Arm Description
Participants will use varenicline (1mg BD) 4-weeks prior to quitting
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting
Intervention Type
Drug
Intervention Name(s)
Varenicline
Other Intervention Name(s)
Champix
Intervention Description
Varenicline 1mg twice daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo 1mg BD
Primary Outcome Measure Information:
Title
Rating of Urges to Smoke 24 Hours and One Week After the Target Quit Date Assessed by Mood and Physical Symptoms Scale
Description
The scale measures tobacco withdrawal symptoms (depressed, irritable, restless, hungry, poor concentration, slept worse than usual) on 5-point scales from Not at all (rated as 1) to Extremely (rated as 5). It also asks 'How much of the time have you felt the urge to smoke in the last week? and 'How strong have these urges been?'; both rated on 6-point scales with higher numbers=higher craving.
Time Frame
24 hours and 7 days after quit date (week 4)
Secondary Outcome Measure Information:
Title
Change in Pre-quit End-expired Carbon Monoxide Reading (CO)
Description
Carbon monoxide concentration is measured in particles per million. It indicates smoke intake. CO was measured at each contact to monitor changes in smoke intake and differences between the study arms.
Time Frame
Baseline - week 8
Title
Change in Pre-quit Cotinine Levels
Description
Differences in baseline cotinine levels were compared with cotinine levels measured 4 weeks after taking the first medication dose.
Time Frame
Weeks 1-4 (the first 4-weeks after first medication dose)
Title
Change in Pre-quit Ratings of Cigarette Satisfaction
Description
Satisfaction measured on a scale of 1-5; "Have you found your cigarettes more or less enjoyable than usual in the last week?" 1= much more and 5 = much less
Time Frame
Baseline - week 4
Title
Change in Pre-quit Cigarette Consumption
Description
Participants reported average number of cigarettes smoked per day every week throughout the four week pre-quit period.
Time Frame
Baseline - week 4
Title
Change in MPSS Scores of Urges to Smoke and Cigarette Withdrawal Symptoms Throughout the First Four Weeks of Abstinence
Description
Change in the Mood and Physical Symptoms Scale (MPSS)*, scores of urges to smoke and cigarette withdrawal symptoms throughout the first four weeks of abstinence (measured weekly from weeks 4-8). * The MPSS measures cigarette withdrawal symptoms. The scale is 1-5, 1 being not at all and 5 being extremely (depressed, irritable, restless, hungry, poor concentration, slept worse than usual).
Time Frame
Week 4 - 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Smokers seeking treatment Aged 18 and over Consenting to take part in the trial Exclusion Criteria: Pregnant or breastfeeding End-stage renal disease Used varenicline in the past 6 months Unable to fill in questionnaires in English Current psychiatric illness Current serious illness including uncontrolled hypertension and recent cardiac event Sensitivity to varenicline currently enrolled in other research projects.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Al-Rehan A A Dhanji, MB BS BSc MRCP
Organizational Affiliation
Queen Mary University of London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tobacco Dependence Research and Treatment Unit
City
London
ZIP/Postal Code
E1 2JH
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
21518946
Citation
Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med. 2011 Apr 25;171(8):770-7. doi: 10.1001/archinternmed.2011.138.
Results Reference
derived

Learn more about this trial

Use of Varenicline for 4-weeks Prior to Quitting

We'll reach out to this number within 24 hrs